These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
90 related items for PubMed ID: 9249251
1. Inhibition of eotaxin-mediated human eosinophil activation and migration by the selective cyclic nucleotide phosphodiesterase type 4 inhibitor rolipram. Santamaria LF, Palacios JM, Beleta J. Br J Pharmacol; 1997 Jul; 121(6):1150-4. PubMed ID: 9249251 [Abstract] [Full Text] [Related]
2. Modulation of eotaxin formation and eosinophil migration by selective inhibitors of phosphodiesterase type 4 isoenzyme. Silva PM, Alves AC, Serra MF, Pires AL, Silva JP, Barreto EO, Cordeiro RS, Jose PJ, Teixeira MM, Lagente V, Martins MA. Br J Pharmacol; 2001 Sep; 134(2):283-94. PubMed ID: 11564646 [Abstract] [Full Text] [Related]
3. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4. Blease K, Burke-Gaffney A, Hellewell PG. Br J Pharmacol; 1998 May; 124(1):229-37. PubMed ID: 9630364 [Abstract] [Full Text] [Related]
4. Beta2-integrin adhesion caused by eotaxin but not IL-5 is blocked by PDE-4 inhibition and beta2-adrenoceptor activation in human eosinophils. Liu J, Muñoz NM, Meliton AY, Zhu X, Lambertino AT, Xu C, Myo S, Myou S, Boetticher E, Johnson M, Leff AR. Pulm Pharmacol Ther; 2004 May; 17(2):73-9. PubMed ID: 15123228 [Abstract] [Full Text] [Related]
5. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol. Dent G, Giembycz MA, Evans PM, Rabe KF, Barnes PJ. J Pharmacol Exp Ther; 1994 Dec; 271(3):1167-74. PubMed ID: 7996422 [Abstract] [Full Text] [Related]
6. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity. Barnette MS, Manning CD, Cieslinski LB, Burman M, Christensen SB, Torphy TJ. J Pharmacol Exp Ther; 1995 May; 273(2):674-9. PubMed ID: 7752069 [Abstract] [Full Text] [Related]
7. Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor. Collado MC, Beleta J, Martinez E, Miralpeix M, Domènech T, Palacios JM, Hernández J. Br J Pharmacol; 1998 Mar; 123(6):1047-54. PubMed ID: 9559885 [Abstract] [Full Text] [Related]
8. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Tenor H, Hatzelmann A, Church MK, Schudt C, Shute JK. Br J Pharmacol; 1996 Aug; 118(7):1727-35. PubMed ID: 8842438 [Abstract] [Full Text] [Related]
11. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram. Souness JE, Maslen C, Webber S, Foster M, Raeburn D, Palfreyman MN, Ashton MJ, Karlsson JA. Br J Pharmacol; 1995 May; 115(1):39-46. PubMed ID: 7647982 [Abstract] [Full Text] [Related]
12. CD28 and secretory immunoglobulin A-dependent activation of eosinophils: inhibition of mediator release by the anti-allergic drug, suplatast tosilate. Woerly G, Decot V, Loiseau S, Loyens M, Chihara J, Ono N, Capron M. Clin Exp Allergy; 2004 Sep; 34(9):1379-87. PubMed ID: 15347370 [Abstract] [Full Text] [Related]
14. Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram. Underwood DC, Osborn RR, Novak LB, Matthews JK, Newsholme SJ, Undem BJ, Hand JM, Torphy TJ. J Pharmacol Exp Ther; 1993 Jul; 266(1):306-13. PubMed ID: 8392555 [Abstract] [Full Text] [Related]
15. A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo. Cooper N, Teixeira MM, Warneck J, Miotla JM, Wills RE, Macari DM, Gristwood RW, Hellewell PG. Br J Pharmacol; 1999 Apr; 126(8):1863-71. PubMed ID: 10372831 [Abstract] [Full Text] [Related]
16. Phosphodiesterase type 4 inhibitor rolipram inhibits activation of monocytes during extracorporeal circulation. Sato Y, Hiramatsu Y, Homma S, Sato M, Sato S, Endo S, Sohara Y. J Thorac Cardiovasc Surg; 2005 Aug; 130(2):346-50. PubMed ID: 16077397 [Abstract] [Full Text] [Related]
17. A comparison of the inhibitory activity of selective PDE4 inhibitors on eosinophil recruitment in guinea pig skin. Teixeira MM, Miotla JM, Cooper N, Gristwood RW, Hellewell PG. Mem Inst Oswaldo Cruz; 1997 Aug; 92 Suppl 2():193-6. PubMed ID: 9698932 [Abstract] [Full Text] [Related]
18. Phosphodiesterase type 4 inhibition of activated polymorphonuclear leukocytes in a simulated extracorporeal circulation model. Sato Y, Hiramatsu Y, Homma S, Sato S, Onizuka M, Sakakibara Y. J Thorac Cardiovasc Surg; 2003 Jan; 125(1):172-7. PubMed ID: 12539001 [Abstract] [Full Text] [Related]
19. Inhibition of PAF-induced expression of CD11b and shedding of L-selectin on human neutrophils and eosinophils by the type IV selective PDE inhibitor, rolipram. Berends C, Dijkhuizen B, de Monchy JG, Dubois AE, Gerritsen J, Kauffman HF. Eur Respir J; 1997 May; 10(5):1000-7. PubMed ID: 9163638 [Abstract] [Full Text] [Related]
20. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia. Moon E, Lee R, Near R, Weintraub L, Wolda S, Lerner A. Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681 [Abstract] [Full Text] [Related] Page: [Next] [New Search]